Project Team Meeting: Agendas & Minutes
Our Project Team Meetings are held every Tuesday, 17:00-18:00 (Central European Time)
If you would like to participate, contact the Project Manager: richard.norman@pistoiaalliance.org
Name | Organisation | Location | Role | Relevant experience & interests |
|---|---|---|---|---|
Francisco J. Fernández | Abvance Biotech | Madrid, ES | Chief Executive Officer | CEO. Structural biologist. Scientific leadership to the antibody drug discovery, business strategy and partnering programmes. |
Jocelyne Fiaux | Novartis | Basel, CH | Head Strategy and Operations Integrated Biologics Profiling | Background in protein chemistry. Experience in biochemical and biophysical characterization, and Developability Assessment of therapeutic proteins and antibodies. |
Laura Hook | GSK | Stevenage, UK | ||
Bryan Jones | Eli Lilly | San Diego, US | Research Fellow | Group Leader for Protein Bio-Sciences group, responsible for expression, purification, biochemical and biophysical characterization of potential therapeutic proteins and antibodies. |
Chris Lloyd | MedImmune | Cambridge, UK | Protein engineer. Research Developability lead for MedImmune. Works on mAbs, bispecific's, ADCs and other novel formats across various therapy areas | |
Carmen Nitsche | Pistoia Alliance | Business Development Lead | ||
Richard Norman | Pistoia Alliance | Gjøvik, NO | Consultant Project Manager | Project Manager. Background in structural biology, and small molecule drug discovery and early development at AstraZeneca. Interested in drug development of biologics, data sharing and the impact which Machine Learning and Artificial Intelligence will have on the Life Sciences. |
Abhinandan Raghavan | Novartis | Basel, CH | ||
Kieran Todd | GSK | Stevenage, UK | Senior Investigator | Bioinformatician providing support to all aspect of the antibody development process, ranging from target identification through to patent support but most heavily focused on lead molecule identification and/or design. |